血清细胞外囊泡中ENO2对弥漫性大B细胞淋巴瘤患者诊断和预后的临床价值

Clinical value of ENO2 in serum extracellular vesicles for the diagnosis and prognosis of diffuse large B-cell lymphoma patients.

作者信息

Yang Ruiyu, Hu Yimin, Liu Qingguo, Huang Pingping

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 288 Nanjing Road, Heping District, Tianjin, 300020, China.

Tianjin Institutes of Health Science, Tianjin, 301600, China.

出版信息

Clin Transl Oncol. 2025 Aug 22. doi: 10.1007/s12094-025-04030-9.

DOI:10.1007/s12094-025-04030-9

PMID:40844644

Abstract

BACKGROUND

This study investigates the differential expression of ENO2 in serum extracellular vesicles (EVs) of patients with diffuse large B cell lymphoma (DLBCL) and its correlation with clinicopathological characteristics and prognosis.

METHODS

Serum samples before receiving treatment, clinicopathological characteristics, and follow-up information were collected from 78 patients with DLBCL, and 40 patients with reactive hyperplasia of lymph nodes (RH) were selected as the control group. ENO2 expression in serum EVs was detected by RT-qPCR and Western blot. The diagnostic value of ENO2 in serum EVs for DLBCL was analyzed by ROC curve. The correlation between ENO2 expression and clinicopathological data was analyzed by chi square test. The 5-year overall survival (OS) was analyzed by Kaplan-Meier method. The COX proportional hazards model was employed for analyzing prognostic risk factors of DLBCL.

RESULTS

ENO2 is highly expressed in serum EVs of DLBCL patients. ENO2 in serum EVs has moderate diagnostic efficacy for DLBCL, with a sensitivity, specificity, and AUC of 0.808, 0.725, and 0.789, respectively. ENO2 expression is closely related to ECOG score, LDH level, Ann Arbor stage, IPI, and Bcl-2. DLBCL patients with age (> 60 years), ECOG (2-4), LDH level (High), Ann Arbor stage (III + IV), IPI score (3-5), Ki-67 (≥ 70%), Bcl-2 (positive), and ENO2 protein (high expression) have lower 5-year OS. ENO2 protein (high expression), ECOG (2-4), Ann Arbor stage (III + IV), and Ki-67 (≥ 70%) are independent prognostic risk factor for DLBCL.

CONCLUSIONS

ENO2 is correlated with the clinicopathological characteristics of DLBCL and is an independent prognostic risk factor.

摘要

背景

本研究调查弥漫性大B细胞淋巴瘤（DLBCL）患者血清细胞外囊泡（EVs）中ENO2的差异表达及其与临床病理特征和预后的相关性。

方法

收集78例DLBCL患者治疗前的血清样本、临床病理特征及随访信息，并选取40例淋巴结反应性增生（RH）患者作为对照组。采用RT-qPCR和Western blot检测血清EVs中ENO2的表达。通过ROC曲线分析血清EVs中ENO2对DLBCL的诊断价值。采用卡方检验分析ENO2表达与临床病理数据的相关性。采用Kaplan-Meier法分析5年总生存率（OS）。采用COX比例风险模型分析DLBCL的预后危险因素。

结果

ENO2在DLBCL患者血清EVs中高表达。血清EVs中的ENO2对DLBCL具有中等诊断效能，敏感性、特异性和AUC分别为0.808、0.725和0.789。ENO2表达与ECOG评分、LDH水平、Ann Arbor分期、IPI和Bcl-2密切相关。年龄（>60岁）、ECOG（2-4）、LDH水平（高）、Ann Arbor分期（III+IV）、IPI评分（3-5）、Ki-67（≥70%）、Bcl-2（阳性）和ENO2蛋白（高表达）的DLBCL患者5年OS较低。ENO2蛋白（高表达）、ECOG（2-4）、Ann Arbor分期（III+IV）和Ki-67（≥70%）是DLBCL的独立预后危险因素。